Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Bioisosteric approach in designing new monastrol derivatives: an investigation on their ADMET prediction using in silico derived parameters.

Hassan SF, Rashid U, Ansari FL, Ul-Haq Z.

J Mol Graph Model. 2013 Sep;45:202-10. doi: 10.1016/j.jmgm.2013.09.002. Epub 2013 Sep 12.

PMID:
24080467
2.

Mechanism of inhibition of human KSP by monastrol: insights from kinetic analysis and the effect of ionic strength on KSP inhibition.

Luo L, Carson JD, Dhanak D, Jackson JR, Huang PS, Lee Y, Sakowicz R, Copeland RA.

Biochemistry. 2004 Dec 7;43(48):15258-66.

PMID:
15568818
3.

Structure of human Eg5 in complex with a new monastrol-based inhibitor bound in the R configuration.

Garcia-Saez I, DeBonis S, Lopez R, Trucco F, Rousseau B, Thuéry P, Kozielski F.

J Biol Chem. 2007 Mar 30;282(13):9740-7. Epub 2007 Jan 23.

4.

Evidence that monastrol is an allosteric inhibitor of the mitotic kinesin Eg5.

Maliga Z, Kapoor TM, Mitchison TJ.

Chem Biol. 2002 Sep;9(9):989-96.

5.

Interaction of the mitotic inhibitor monastrol with human kinesin Eg5.

DeBonis S, Simorre JP, Crevel I, Lebeau L, Skoufias DA, Blangy A, Ebel C, Gans P, Cross R, Hackney DD, Wade RH, Kozielski F.

Biochemistry. 2003 Jan 21;42(2):338-49.

PMID:
12525161
6.

Monastrol inhibition of the mitotic kinesin Eg5.

Cochran JC, Gatial JE 3rd, Kapoor TM, Gilbert SP.

J Biol Chem. 2005 Apr 1;280(13):12658-67. Epub 2005 Jan 23.

7.

Disparity in allosteric interactions of monastrol with Eg5 in the presence of ADP and ATP: a difference FT-IR investigation.

Wojcik EJ, Dalrymple NA, Alford SR, Walker RA, Kim S.

Biochemistry. 2004 Aug 10;43(31):9939-49.

PMID:
15287721
8.

A structural model for monastrol inhibition of dimeric kinesin Eg5.

Krzysiak TC, Wendt T, Sproul LR, Tittmann P, Gross H, Gilbert SP, Hoenger A.

EMBO J. 2006 May 17;25(10):2263-73. Epub 2006 Apr 27.

9.
10.

Molecular dissection of the inhibitor binding pocket of mitotic kinesin Eg5 reveals mutants that confer resistance to antimitotic agents.

Brier S, Lemaire D, DeBonis S, Forest E, Kozielski F.

J Mol Biol. 2006 Jul 7;360(2):360-76. Epub 2006 May 15.

PMID:
16780877
11.

Inhibitors of kinesin Eg5: antiproliferative activity of monastrol analogues against human glioblastoma cells.

Müller C, Gross D, Sarli V, Gartner M, Giannis A, Bernhardt G, Buschauer A.

Cancer Chemother Pharmacol. 2007 Feb;59(2):157-64. Epub 2006 May 16.

PMID:
16703323
12.

Identification of the protein binding region of S-trityl-L-cysteine, a new potent inhibitor of the mitotic kinesin Eg5.

Brier S, Lemaire D, Debonis S, Forest E, Kozielski F.

Biochemistry. 2004 Oct 19;43(41):13072-82.

PMID:
15476401
13.

New chemical tools for investigating human mitotic kinesin Eg5.

Klein E, DeBonis S, Thiede B, Skoufias DA, Kozielski F, Lebeau L.

Bioorg Med Chem. 2007 Oct 1;15(19):6474-88. Epub 2007 Jun 10.

PMID:
17587586
14.

Structural basis for inhibition of Eg5 by dihydropyrimidines: stereoselectivity of antimitotic inhibitors enastron, dimethylenastron and fluorastrol.

Kaan HY, Ulaganathan V, Rath O, Prokopcová H, Dallinger D, Kappe CO, Kozielski F.

J Med Chem. 2010 Aug 12;53(15):5676-83. doi: 10.1021/jm100421n.

PMID:
20597485
15.

Thermodynamics of nucleotide and inhibitor binding to wild-type and ispinesib-resistant forms of human kinesin spindle protein.

Sheth PR, Basso A, Duca JS, Lesburg CA, Ogas P, Gray K, Nale L, Mannarino AF, Prongay AJ, Le HV.

Biochemistry. 2009 Nov 24;48(46):11045-55. doi: 10.1021/bi900946r.

PMID:
19824700
16.

Structure based virtual screening-driven identification of monastrol as a potent urease inhibitor.

Rashid U, Batool I, Wadood A, Khan A, ul-Haq Z, Chaudhary MI, Ansari FL.

J Mol Graph Model. 2013 Jun;43:47-57. doi: 10.1016/j.jmgm.2013.04.006. Epub 2013 Apr 30.

PMID:
23727895
17.

Mutations in the human kinesin Eg5 that confer resistance to monastrol and S-trityl-L-cysteine in tumor derived cell lines.

Tcherniuk S, van Lis R, Kozielski F, Skoufias DA.

Biochem Pharmacol. 2010 Mar 15;79(6):864-72. doi: 10.1016/j.bcp.2009.11.001. Epub 2009 Nov 6.

PMID:
19896928
18.

Discovery of novel spiro 1,3,4-thiadiazolines as potent, orally bioavailable and brain penetrant KSP inhibitors.

Mansoor UF, Angeles AR, Dai C, Yang L, Vitharana D, Basso AD, Gray K, Tang H, Liu M, Liang L, Allbritton O, Siddiqui MA.

Bioorg Med Chem. 2015 May 15;23(10):2424-34. doi: 10.1016/j.bmc.2015.03.052. Epub 2015 Mar 27.

PMID:
25868746
19.

Mitotic slippage and expression of survivin are linked to differential sensitivity of human cancer cell-lines to the Kinesin-5 inhibitor monastrol.

Asraf H, Avunie-Masala R, Hershfinkel M, Gheber L.

PLoS One. 2015 Jun 2;10(6):e0129255. doi: 10.1371/journal.pone.0129255. eCollection 2015.

20.

Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein.

Peters T, Lindenmaier H, Haefeli WE, Weiss J.

Naunyn Schmiedebergs Arch Pharmacol. 2006 Jan;372(4):291-9. Epub 2005 Dec 20.

PMID:
16365780

Supplemental Content

Support Center